Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
Cost-benefit analysis of new cancer medicines: The difficult choices of governments
Short-course radiation as effective as standard treatment for breast cancer patients choosing reconstruction after mastectomy
OncoAlert Round Up for September 22-28, 2023
OncoAlert Round Up for September 15-21, 2023
OncoAlert Round Up for September 8-14, 2023
Treating cancer in the heart of the Ukraine conflict
The 5-year long-term outcomes of radiation technique for locally advanced NSCLC
OncoAlert Round Up for September 1-7, 2023
Reducing stigma for lung cancer and other smoking-related respiratory diseases
Part 6: Which different PARP inhibitors are available
Part 7: Similarities and Differences